Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna
R
R
Merck & Co., Inc., Whitehouse Station, New Jersey, USA. rajesh_krishna@merck.com
Bergman
A J
AJ
Jin
B
B
Fallon
M
M
Cote
J
J
Van Hoydonck
P
P
Laethem
T
T
Gendrano
I N
IN
Van Dyck
K
K
Hilliard
D
D
Laterza
O
O
Snyder
K
K
Chavez-Eng
C
C
Lutz
R
R
Chen
J
J
Bloomfield
D M
DM
De Smet
M
M
Van Bortel
L M
LM
Gutierrez
M
M
Al-Huniti
N
N
Dykstra
K
K
Gottesdiener
K M
KM
Wagner
J A
JA
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D053480:Cholesterol Ester Transfer Proteins / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D012016:Reference Values; D012307:Risk Factors; D012680:Sensitivity and Specificity; D055815:Young Adult
D053480:Cholesterol Ester Transfer Proteins; D023303:Oxazolidinones; C530884:anacetrapib